The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.

Luo C, He D, Yang H, Zhu C, Zhu J, Hu Z

African health sciences1 Sept 2022Cited by 4 (Europe PMC)

PMID36910413PMCIDPMC9993257DOI10.4314/ahs.v22i3.28PepBankPUB-36910413

Summary

IntroductionThe efficacy of liraglutide on renal function in type 2 diabetes remains controversial. We conduct a systematic review and meta-analysis to explore the influence of liraglutide versus placebo on renal function in type 2 diabetes.MethodsWe search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes. This meta-analysis is performed using the random-effect model.ResultsSeven RCTs are included in the meta-analysis. Overall, compared with control group in type 2 diabetes, liraglutide treatment shows no obvious effect on GFR (SMD=0.02; 95% CI=-0.43 to 0.47; P=0.94), RBF (SMD=-0.28; 95% CI=-0.80 to 0.24; P=0.29) or death (RR=1.93; 95% CI=0.71 to 5.21; P=0.20), but is associated with significantly decreased ACR (SMD=-0.82; 95% CI=-1.39 to -0.26; P=0.004) and systolic blood pressure (MD=-9.60; 95% CI=-17.46 to -1.73; P=0.02), as well as increased heart rate (MD=5.39; 95% CI=3.26 to 7.52; P<0.00001).ConclusionsLiraglutide treatment may provide some benefits for protecting renal function in type 2 diabetes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis of RCTs found no obvious effect of liraglutide versus placebo on GFR.
In plain wordsIn adults with type 2 diabetes, pooled trials showed no clear effect of liraglutide on kidney filtration compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeGlomerular filtration rate (GFR)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
SMD, GFR
0.02 SMD
liraglutide vs placebo
Source sentences
Summary
liraglutide treatment shows no obvious effect on GFR (SMD=0.02; 95% CI=-0.43 to 0.47; P=0.94)
2 context sentences(design, population, supporting numbers)
Summary · context
We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes.
Summary · context
Seven RCTs are included in the meta-analysis.
Show in the study text Report a problemFND-3691041301
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis of RCTs found no obvious effect of liraglutide versus placebo on renal blood flow.
In plain wordsIn adults with type 2 diabetes, pooled trials showed no clear effect of liraglutide on blood flow to the kidneys compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeRenal blood flow (RBF)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
SMD, RBF
−0.28 SMD
liraglutide vs placebo
Source sentences
Summary
RBF (SMD=-0.28; 95% CI=-0.80 to 0.24; P=0.29)
2 context sentences(design, population, supporting numbers)
Summary · context
We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes.
Summary · context
Seven RCTs are included in the meta-analysis.
Show in the study text Report a problemFND-3691041302
03HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis of RCTs found no obvious effect of liraglutide versus placebo on death.
In plain wordsIn adults with type 2 diabetes, pooled trials showed no clear difference in deaths with liraglutide compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeDeath
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Measurements
RR, death
1.93 RR
liraglutide vs placebo
Source sentences
Summary
death (RR=1.93; 95% CI=0.71 to 5.21; P=0.20)
2 context sentences(design, population, supporting numbers)
Summary · context
We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes.
Summary · context
Seven RCTs are included in the meta-analysis.
Show in the study text Report a problemFND-3691041303
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis of RCTs found that liraglutide significantly decreased ACR versus placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials linked liraglutide to lower urine albumin than placebo.
Peptide
Liraglutide
Outcome
DecreaseAlbumin-to-creatinine ratio (ACR)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
SMD, ACR
−0.82 SMD
liraglutide vs placebo
Source sentences
Summary
significantly decreased ACR (SMD=-0.82; 95% CI=-1.39 to -0.26; P=0.004)
2 context sentences(design, population, supporting numbers)
Summary · context
We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes.
Summary · context
Seven RCTs are included in the meta-analysis.
Show in the study text Report a problemFND-3691041304
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a meta-analysis of RCTs found that liraglutide significantly decreased systolic blood pressure versus placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials linked liraglutide to lower systolic blood pressure than placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
MD, systolic blood pressure
−9.6 MD
liraglutide vs placebo
Source sentences
Summary
systolic blood pressure (MD=-9.60; 95% CI=-17.46 to -1.73; P=0.02)
2 context sentences(design, population, supporting numbers)
Summary · context
We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes.
Summary · context
Seven RCTs are included in the meta-analysis.
Show in the study text Report a problemFND-3691041305
06HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, a meta-analysis of RCTs found that liraglutide increased heart rate versus placebo.
In plain wordsIn adults with type 2 diabetes, pooled trials linked liraglutide to a higher heart rate than placebo.
Peptide
Liraglutide
Outcome
IncreaseHeart rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
MD, heart rate
5.39 MD
liraglutide vs placebo
Source sentences
Summary
increased heart rate (MD=5.39; 95% CI=3.26 to 7.52; P<0.00001)
2 context sentences(design, population, supporting numbers)
Summary · context
We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes.
Summary · context
Seven RCTs are included in the meta-analysis.
Show in the study text Report a problemFND-3691041306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.